LYT-200

About Gallop Oncology

Gallop Oncology is a clinical-stage, wholly-owned subsidiary of PureTech Health developing first-in-class therapies targeting galectin-9. Its lead asset, LYT-200, has received FDA Fast Track and Orphan Drug designations for acute myeloid leukemia (AML) and head and neck squamous cell carcinoma (HNSCC), demonstrating a dual mechanism of action that combines direct tumor suppression with immune modulation. The company is advancing LYT-200 in Phase 1/2 trials for these high-need indications, with initial clinical data showing promising safety and activity. Gallop represents a focused effort to address significant unmet needs in oncology through a novel biological pathway.

About Gallop Oncology

Gallop Oncology is a clinical-stage, wholly-owned subsidiary of PureTech Health developing first-in-class therapies targeting galectin-9. Its lead asset, LYT-200, has received FDA Fast Track and Orphan Drug designations for acute myeloid leukemia (AML) and head and neck squamous cell carcinoma (HNSCC), demonstrating a dual mechanism of action that combines direct tumor suppression with immune modulation. The company is advancing LYT-200 in Phase 1/2 trials for these high-need indications, with initial clinical data showing promising safety and activity. Gallop represents a focused effort to address significant unmet needs in oncology through a novel biological pathway.

About PureTech Health

PureTech Health is a Boston-based biotech studio that creates and funds separate companies around innovative scientific discoveries, de-risking development and capturing value through equity and royalties. Its model has proven exceptionally successful, boasting a 6x higher clinical success rate than the industry average and delivering three FDA-approved therapies. The company's strategy leverages a deep network of academic collaborators and seasoned leadership to build a diversified portfolio across immunology, neurology, and gastroenterology.

Therapeutic Areas